Kleber et al reported the use of the Freiberger Comorbidity Index (FCI) in patients with multiple myeloma. This can help to identify a patient who may benefit from more aggressive management. The authors are from the University of Freiburg in Germany.
Patient selection: multiple myeloma
Parameters:
(1) Karnofsky Performance Status (KPS)
(2) lung disease
(3) estimated GFR by the MDRD equation in mL per min per 1.73 sq meter
Parameter |
Finding |
Points |
Karnofsky Performance Status |
> 70% |
0 |
|
<= 70% |
1 |
lung disease |
none or mild |
0 |
|
moderate or severe |
1 |
estimated GFR |
>= 30 |
0 |
|
< 30 |
1 |
total score =
= SUM(points for all 3 parameters)
Interpretation:
• minimum score: 0
• maximum score: 3
• The higher the score the worse the overall survival.
Total Score |
Median Overall Survival |
0 |
118 months (10 years) |
1 |
53 months |
2 or 3 |
25 months |
Purpose: To evluate a patient with multiple myeloma using the Freiburger Comorbidity Index (FCI) of Kleber et al.
Objective: comorbid conditions
ICD-10: C90,